## Chi V Dang

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4325858/publications.pdf

Version: 2024-02-01

216 papers 51,046 citations

89 h-index 208 g-index

223 all docs 223 docs citations

times ranked

223

56407 citing authors

#	Article	IF	CITATIONS
1	HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 2006, 3, 177-185.	7.2	3,112
2	c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 2005, 435, 839-843.	13.7	2,618
3	MYC on the Path to Cancer. Cell, 2012, 149, 22-35.	13.5	2,577
4	Otto Warburg's contributions to current concepts of cancer metabolism. Nature Reviews Cancer, 2011, 11, 325-337.	12.8	2,566
5	c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature, 2009, 458, 762-765.	13.7	1,801
6	c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism. Molecular and Cellular Biology, 1999, 19, 1-11.	1.1	1,501
7	From Krebs to clinic: glutamine metabolism to cancer therapy. Nature Reviews Cancer, 2016, 16, 619-634.	12.8	1,367
8	Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. Cell, 2011, 146, 772-784.	13.5	1,304
9	Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 2008, 40, 43-50.	9.4	1,203
10	Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 2037-2042.	3.3	1,150
11	Cancer's Molecular Sweet Tooth and the Warburg Effect: Figure 1 Cancer Research, 2006, 66, 8927-8930.	0.4	1,086
12	HIF-1 Regulates Cytochrome Oxidase Subunits to Optimize Efficiency of Respiration in Hypoxic Cells. Cell, 2007, 129, 111-122.	13.5	1,068
13	Oncogenic alterations of metabolism. Trends in Biochemical Sciences, 1999, 24, 68-72.	3.7	989
14	The c-Myc target gene network. Seminars in Cancer Biology, 2006, 16, 253-264.	4.3	989
15	Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in Humans. Genome Research, 2003, 13, 2363-2371.	2.4	954
16	Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells. Cell Metabolism, 2012, 15, 110-121.	7.2	923
17	MYC, Metabolism, and Cancer. Cancer Discovery, 2015, 5, 1024-1039.	7.7	919
18	Links between metabolism and cancer. Genes and Development, 2012, 26, 877-890.	2.7	846

#	Article	IF	CITATIONS
19	HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL-Deficient Renal Cell Carcinoma by Repression of C-MYC Activity. Cancer Cell, 2007, 11, 407-420.	7.7	760
20	MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities. Clinical Cancer Research, 2009, 15, 6479-6483.	3.2	738
21	Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc. Journal of Biological Chemistry, 2000, 275, 21797-21800.	1.6	708
22	Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. Cancer Cell, 2010, 18, 207-219.	7.7	707
23	Drugging the 'undruggable' cancer targets. Nature Reviews Cancer, 2017, 17, 502-508.	12.8	620
24	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	7.7	601
25	Multifaceted roles of glycolytic enzymes. Trends in Biochemical Sciences, 2005, 30, 142-150.	3.7	570
26	Digoxin and other cardiac glycosides inhibit HIF- $\hat{l}$ ± synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 19579-19586.	3.3	568
27	Hypoxia-Inducible Factor $1$ and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase $2$ and Pyruvate Dehydrogenase Kinase $1$ . Molecular and Cellular Biology, 2007, 27, 7381-7393.	1.1	540
28	The interplay between MYC and HIF in cancer. Nature Reviews Cancer, 2008, 8, 51-56.	12.8	535
29	Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis. Molecular and Cellular Biology, 2005, 25, 6225-6234.	1.1	527
30	MYC, Metabolism, Cell Growth, and Tumorigenesis. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014217-a014217.	2.9	494
31	HIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo. Cancer Cell, 2007, 12, 230-238.	7.7	466
32	Global mapping of c-Myc binding sites and target gene networks in human B cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17834-17839.	3.3	462
33	Translocations involving c-myc and c-myc function. Oncogene, 2001, 20, 5595-5610.	2.6	440
34	Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1. Cancer Research, 2010, 70, 8981-8987.	0.4	439
35	An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biology, 2003, 4, R69.	13.9	433
36	Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8983-8988.	3.3	399

#	Article	IF	CITATIONS
37	Targeting cancer metabolism in the era of precision oncology. Nature Reviews Drug Discovery, 2022, 21, 141-162.	21.5	385
38	c-Myc Is Glycosylated at Threonine 58, a Known Phosphorylation Site and a Mutational Hot Spot in Lymphomas. Journal of Biological Chemistry, 1995, 270, 18961-18965.	1.6	365
39	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood, 2009, 114, 5473-5480.	0.6	364
40	Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3384-3389.	3.3	355
41	Rethinking the Warburg Effect with Myc Micromanaging Glutamine Metabolism. Cancer Research, 2010, 70, 859-862.	0.4	353
42	Function of the c-Myc Oncogenic Transcription Factor. Experimental Cell Research, 1999, 253, 63-77.	1,2	332
43	Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression. Journal of Biological Chemistry, 2001, 276, 7919-7926.	1.6	322
44	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. Journal of Clinical Investigation, 2015, 125, 2293-2306.	3.9	319
45	Evaluation of Myc E-Box Phylogenetic Footprints in Glycolytic Genes by Chromatin Immunoprecipitation Assays. Molecular and Cellular Biology, 2004, 24, 5923-5936.	1.1	312
46	Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nature Genetics, 2010, 42, 840-850.	9.4	295
47	Blocking Lactate Export by Inhibiting the Myc Target MCT1 Disables Glycolysis and Glutathione Synthesis. Cancer Research, 2014, 74, 908-920.	0.4	291
48	Neoplastic Transformation of RK3E by Mutant $\hat{l}^2$ -Catenin Requires Deregulation of Tcf/Lef Transcription but Not Activation of c- <i>myc</i> Expression. Molecular and Cellular Biology, 1999, 19, 5696-5706.	1.1	287
49	MYC and metabolism on the path to cancer. Seminars in Cell and Developmental Biology, 2015, 43, 11-21.	2.3	253
50	MYC and Prostate Cancer. Genes and Cancer, 2010, 1, 617-628.	0.6	245
51	Global Regulation of Nucleotide Biosynthetic Genes by c-Myc. PLoS ONE, 2008, 3, e2722.	1.1	239
52	Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nature Structural and Molecular Biology, 2016, 23, 522-530.	3.6	231
53	MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells. Cell Metabolism, 2015, 22, 1009-1019.	7.2	217
54	Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. Nature, 1989, 337, 664-666.	13.7	214

#	Article	IF	CITATIONS
55	MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6539-6544.	3.3	211
56	Activation of Transferrin Receptor $1$ by c-Myc Enhances Cellular Proliferation and Tumorigenesis. Molecular and Cellular Biology, 2006, 26, 2373-2386.	1.1	210
57	Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells?. Cell Cycle, 2010, 9, 3884-3886.	1.3	209
58	Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4578-4583.	3.3	207
59	Histopathological and Molecular Prognostic Markers in Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2004, 63, 441-449.	0.9	203
60	Repression of BET activity sensitizes homologous recombination–proficient cancers to PARP inhibition. Science Translational Medicine, 2017, 9, .	5.8	180
61	The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6649-6654.	3.3	179
62	Acid Suspends the Circadian Clock in Hypoxia through Inhibition of mTOR. Cell, 2018, 174, 72-87.e32.	13.5	172
63	Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 10551-10563.	2.9	163
64	Clock Regulation of Metabolites Reveals Coupling between Transcription and Metabolism. Cell Metabolism, 2017, 25, 961-974.e4.	7.2	162
65	Function of the câ€Myc oncoprotein. FASEB Journal, 1992, 6, 3065-3072.	0.2	155
66	Therapeutic targeting of cancer cell metabolism. Journal of Molecular Medicine, 2011, 89, 205-212.	1.7	151
67	Cell-Type Independent MYC Target Genes Reveal a Primordial Signature Involved in Biomass Accumulation. PLoS ONE, 2011, 6, e26057.	1.1	147
68	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Cancer Research, 2015, 75, 3355-3364.	0.4	129
69	Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical Cancer Research, 2015, 21, 3263-3273.	3.2	129
70	Identification of a large Myc-binding protein that contains RCC1-like repeats. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9172-9177.	3.3	125
71	Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Experimental Hematology, 2014, 42, 247-251.	0.2	125
72	Effects of hypoxia on tumor metabolism. Cancer and Metastasis Reviews, 2007, 26, 291-298.	2.7	123

#	Article	IF	CITATIONS
73	The role of long noncoding RNAs in cancer: the dark matter matters. Current Opinion in Genetics and Development, 2018, 48, 8-15.	1.5	122
74	$17\hat{l}^2$ -Estradiol Inhibits Apoptosis of Endothelial Cells. Biochemical and Biophysical Research Communications, 1997, 237, 372-381.	1.0	120
75	The MYC Oncogene Cooperates with Sterol-Regulated Element-Binding Protein to Regulate Lipogenesis Essential for Neoplastic Growth. Cell Metabolism, 2019, 30, 556-572.e5.	7.2	120
76	c-Myc Overexpression Uncouples DNA Replication from Mitosis. Molecular and Cellular Biology, 1999, 19, 5339-5351.	1.1	119
77	Alterations in Nucleolar Structure and Gene Expression Programs in Prostatic Neoplasia Are Driven by the MYC Oncogene. American Journal of Pathology, 2011, 178, 1824-1834.	1.9	113
78	MYC Overexpression Induces Prostatic Intraepithelial Neoplasia and Loss of Nkx3.1 in Mouse Luminal Epithelial Cells. PLoS ONE, 2010, 5, e9427.	1.1	113
79	Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress. Cell Research, 2016, 26, 1112-1130.	5.7	112
80	c-Myc Overexpression Causes Anaplasia in Medulloblastoma. Cancer Research, 2006, 66, 673-681.	0.4	111
81	Characterization of Nucleophosmin (B23) as a Myc Target by Scanning Chromatin Immunoprecipitation. Journal of Biological Chemistry, 2001, 276, 48285-48291.	1.6	108
82	Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. Journal of Bioenergetics and Biomembranes, 1997, 29, 345-354.	1.0	105
83	Arsenic inhibition of telomerase transcription leads to genetic instability. Journal of Clinical Investigation, 2001, 108, 1541-1547.	3.9	101
84	A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5313-5318.	3.3	99
85	The great MYC escape in tumorigenesis. Cancer Cell, 2005, 8, 177-178.	7.7	99
86	Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH). Journal of Medicinal Chemistry, 2017, 60, 9184-9204.	2.9	98
87	Elevated Extracellular Calcium Can Prevent Apoptosis via the Calcium-Sensing Receptor. Biochemical and Biophysical Research Communications, 1998, 249, 325-331.	1.0	96
88	IRE1α RNase–dependent lipid homeostasis promotes survival in Myc-transformed cancers. Journal of Clinical Investigation, 2018, 128, 1300-1316.	3.9	96
89	A Nontranscriptional Role for HIF- $1\hat{l}\pm$ as a Direct Inhibitor of DNA Replication. Science Signaling, 2013, 6, ra10.	1.6	95
90	Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy. Trends in Cell Biology, 2018, 28, 201-212.	3.6	94

#	Article	IF	CITATIONS
91	Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. Journal of the American Association for Laboratory Animal Science, 2008, 47, 37-40.	0.6	89
92	MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Research, 2018, 78, 64-74.	0.4	87
93	A PERK–miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival. Nature Cell Biology, 2018, 20, 104-115.	4.6	86
94	EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect. Oncotarget, 2017, 8, 9557-9571.	0.8	82
95	Isotopically nonstationary 13C flux analysis of Myc-induced metabolic reprogramming in B-cells. Metabolic Engineering, 2013, 15, 206-217.	3.6	81
96	Treatment of Pancreatic Cancer Patient–Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Clinical Cancer Research, 2017, 23, 5639-5647.	3.2	76
97	Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Current Opinion in Hematology, 2005, 12, 1-6.	1.2	74
98	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood, 2005, 106, 304-310.	0.6	74
99	Biology and treatment of Burkitt's lymphoma. Current Opinion in Hematology, 2007, 14, 375-381.	1.2	74
100	An Epigenetic Pathway Regulates Sensitivity of Breast Cancer Cells to HER2 Inhibition via FOXO/c-Myc Axis. Cancer Cell, 2015, 28, 472-485.	7.7	74
101	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid InÂVivo Metabolic Rewiring and Vulnerability to Combination Therapy. Cell Reports, 2020, 30, 1798-1810.e4.	2.9	73
102	MYC, microRNAs and glutamine addiction in cancers. Cell Cycle, 2009, 8, 3243-3245.	1.3	68
103	hTERT Gene Amplification and Increased mRNA Expression in Central Nervous System Embryonal Tumors. American Journal of Pathology, 2003, 162, 1763-1769.	1.9	66
104	Unique conformation of cancer autoantigen B23 in hepatoma: A mechanism for specificity in the autoimmune response. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12361-12366.	3.3	63
105	Increased Expression of TATA-Binding Protein, the Central Transcription Factor, Can Contribute to Oncogenesis. Molecular and Cellular Biology, 2003, 23, 3043-3051.	1.1	62
106	Evaluation of LDH-A and Glutaminase Inhibition <i>In Vivo</i> by Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopy of Tumors. Cancer Research, 2013, 73, 4190-4195.	0.4	61
107	PKM2 Tyrosine Phosphorylation and Glutamine Metabolism Signal a Different View of the Warburg Effect. Science Signaling, 2009, 2, pe75.	1.6	60
108	De novo synthesis of serine and glycine fuels purine nucleotide biosynthesis in human lung cancer tissues. Journal of Biological Chemistry, 2019, 294, 13464-13477.	1.6	58

#	Article	IF	CITATIONS
109	The Normal and Morbid Biology of Fibrinogen. American Journal of Medicine, 1989, 87, 567-576.	0.6	57
110	Could MYC Induction of Mitochondrial Biogenesis be linked to ROS Production and Genomic Instability?. Cell Cycle, 2005, 4, 1465-1466.	1.3	57
111	Enigmatic MYC Conducts an Unfolding Systems Biology Symphony. Genes and Cancer, 2010, 1, 526-531.	0.6	56
112	High molecular mass amino acyl-tRNA synthetase complexes in eukaryotes. FEBS Letters, 1982, 142, 1-6.	1.3	54
113	The Myc Target Gene JPO1/CDCA7 Is Frequently Overexpressed in Human Tumors and Has Limited Transforming Activity In vivo. Cancer Research, 2005, 65, 5620-5627.	0.4	53
114	Normal and cancer cell metabolism: lymphocytes and lymphoma. FEBS Journal, 2012, 279, 2598-2609.	2.2	53
115	Conceptual Framework for Cutting the Pancreatic Cancer Fuel Supply. Clinical Cancer Research, 2012, 18, 4285-4290.	3.2	52
116	A Novel c-Myc- responsive Gene, JPO1, Participates in Neoplastic Transformation. Journal of Biological Chemistry, 2001, 276, 48276-48284.	1.6	51
117	A Time for MYC: Metabolism and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 79-83.	2.0	49
118	Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia–cell cycle dual reporter. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12486-12491.	3.3	48
119	Isolation of Bone Marrow–Derived Stem Cells using Density-Gradient Separation. Experimental Hematology, 2007, 35, 335-341.	0.2	47
120	Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3534-3539.	3.3	47
121	Cyclin A Links c-Myc to Adhesion-independent Cell Proliferation. Journal of Biological Chemistry, 1995, 270, 15923-15925.	1.6	42
122	Conditional Deletion of c-myc Does Not Impair Liver Regeneration. Cancer Research, 2006, 66, 5608-5612.	0.4	40
123	Mammalian BUB1 Protein Kinases: Map Positions andin VivoExpression. Genomics, 1997, 46, 379-388.	1.3	38
124	Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma― Clinical Cancer Research, 2017, 23, 1629-1637.	3.2	38
125	p32 (C1QBP) and Cancer Cell Metabolism: Is the Warburg Effect a Lot of Hot Air?. Molecular and Cellular Biology, 2010, 30, 1300-1302.	1.1	37
126	Time-Dependent c-Myc Transactomes Mapped by Array-Based Nuclear Run-On Reveal Transcriptional Modules in Human B Cells. PLoS ONE, 2010, 5, e9691.	1.1	37

#	Article	IF	CITATIONS
127	Rat liver histidyl-tRNA synthetase. Purification and inhibition by the myositis-specific anti-Jo-1 autoantibody. Biochemical and Biophysical Research Communications, 1984, 120, 15-21.	1.0	36
128	The c-Myc Target Gene Rcl (C6orf108) Encodes a Novel Enzyme, Deoxynucleoside 5′-monophosphate N-Glycosidase. Journal of Biological Chemistry, 2007, 282, 8150-8156.	1.6	36
129	c-Myc oncoprotein function. Biochimica Et Biophysica Acta: Reviews on Cancer, 1991, 1072, 103-113.	3.3	32
130	Localization of the Human Mxi1 Transcription Factor Gene (MXI1) to Chromosome 10q24-q25. Genomics, 1994, 21, 669-672.	1.3	32
131	Evidence for involvement of calpain in c-Myc proteolysis in vivo. Archives of Biochemistry and Biophysics, 2002, 400, 151-161.	1.4	32
132	Stress eating and tuning out: Cancer cells re-wire metabolism to counter stress. Critical Reviews in Biochemistry and Molecular Biology, 2013, 48, 609-619.	2.3	32
133	Genomic Organization of HumanMXI1, a Putative Tumor Suppressor Gene. Genomics, 1996, 32, 466-470.	1.3	31
134	Role of oncogenic transcription factor c-Myc in cell cycle regulation, apoptosis and metabolism. Journal of Biomedical Science, 1997, 4, 269-278.	2.6	31
135	Cancer genetics: Tumor suppressor meets oncogene. Current Biology, 1999, 9, R62-R65.	1.8	31
136	MYC, Metabolic Synthetic Lethality, and Cancer. Recent Results in Cancer Research, 2016, 207, 73-91.	1.8	31
137	Myc Regulation of a Mitochondrial Trafficking Network Mediates Tumor Cell Invasion and Metastasis. Molecular and Cellular Biology, 2019, 39, .	1.1	31
138	High molecular weight complexes of eukaryotic aminoacyl-trna synthetases. International Journal of Biochemistry & Cell Biology, 1982, 14, 539-543.	0.8	30
139	The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice. PLoS ONE, 2015, 10, e0133633.	1.1	30
140	Shedding Light on the Dark Cancer Genomes: Long Noncoding RNAs as Novel Biomarkers and Potential Therapeutic Targets for Cancer. Molecular Cancer Therapeutics, 2018, 17, 1816-1823.	1.9	30
141	MYC-induced metabolic stress and tumorigenesis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1870, 43-50.	3.3	30
142	Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties. Journal of Medicinal Chemistry, 2020, 63, 10984-11011.	2.9	30
143	Human T-cell Leukemia Virus Type I Tax Masks c-Myc Function through a cAMP-dependent Pathway. Journal of Biological Chemistry, 1996, 271, 9730-9738.	1.6	29
144	Multienzyme complexes of eukaryotic aminoacyl-tRNA synthetases. Bioscience Reports, 1983, 3, 527-538.	1.1	27

#	Article	IF	CITATIONS
145	Identification and characterization of the novel centrosome-associated protein CCCAP. Gene, 2003, 303, 35-46.	1.0	27
146	A metabolic perspective of Peto's paradox and cancer. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140223.	1.8	27
147	In silico identification of transcriptional regulators associated with c-Myc. Nucleic Acids Research, 2004, 32, 4955-4961.	6.5	26
148	Fine-tuned amplification in cells. Nature, 2014, 511, 417-418.	13.7	26
149	Tobacco-alcohol amblyopia: A proposed biochemical basis for pathogenesis. Medical Hypotheses, 1981, 7, 1317-1328.	0.8	25
150	Myc-mediated transcriptional regulation of the mitochondrial chaperone TRAP1 controls primary and metastatic tumor growth. Journal of Biological Chemistry, 2019, 294, 10407-10414.	1.6	25
151	Drugging the "Undruggable―MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. Cancer Research, 2021, 81, 1627-1632.	0.4	25
152	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia, 2019, 33, 2429-2441.	3.3	24
153	Studying Myc's Role in Metabolism Regulation. Methods in Molecular Biology, 2013, 1012, 213-219.	0.4	24
154	Antimalarial therapy prevents Myc-induced lymphoma. Journal of Clinical Investigation, 2008, 118, 15-17.	3.9	24
155	Cancer Cell Metabolism: There Is No ROS for the Weary. Cancer Discovery, 2012, 2, 304-307.	7.7	22
156	Anoxic Fibroblasts Activate a Replication Checkpoint That Is Bypassed By E1a. Molecular and Cellular Biology, 2003, 23, 9032-9045.	1.1	21
157	Discovering robust protein biomarkers for disease from relative expression reversals in 2-D DIGE data Proteomics, 2007, 7, 1197-1207.	1.3	21
158	MicroRNA deregulation in polycythemia vera and essential thrombocythemia patients. Blood Cells, Molecules, and Diseases, 2013, 50, 190-195.	0.6	21
159	Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	21
160	Interactions of aminoacyl-tRNA synthetases in high-molecular-weight multienzyme complexes from rat liver. BBA - Proteins and Proteomics, 1985, 829, 319-326.	2.1	20
161	A Strategy to Identify Differentially Expressed Genes Using Representational Difference Analysis and cDNA Arrays. Analytical Biochemistry, 2001, 288, 141-148.	1.1	20
162	Oncogenic alterations of metabolism and the Warburg effect. Drug Discovery Today Disease Mechanisms, 2005, 2, 233-238.	0.8	20

#	Article	IF	CITATIONS
163	c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene, 2001, 20, 6084-6094.	2.6	19
164	Correspondence: Oncogenic MYC persistently upregulates the molecular clock component REV-ERBα. Nature Communications, 2017, 8, 14862.	5.8	17
165	Application of a nitrocellulose immunoassay for quantitation of proteins secreted in culture media. Analytical Biochemistry, 1986, 158, 262-267.	1.1	15
166	Histidyl-tRNA synthetase, the myositis Jo-1 antigen, is cytoplasmic and unassociated with the cytoskeletal framework. Experimental Cell Research, 1986, 164, 261-266.	1.2	14
167	Web of the Extended Myc Network Captures Metabolism for Tumorigenesis. Cancer Cell, 2015, 27, 160-162.	7.7	14
168	Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells. Bioorganic and Medicinal Chemistry, 2011, 19, 7057-7062.	1.4	12
169	Role of aerobic glycolysis in genetically engineered mouse models of cancer. BMC Biology, 2013, 11, 3.	1.7	12
170	ChIP-PED enhances the analysis of ChIP-seq and ChIP-chip data. Bioinformatics, 2013, 29, 1182-1189.	1.8	12
171	Tilting MYC toward cancer cell death. Trends in Cancer, 2021, 7, 982-994.	3.8	12
172	High molecular weight complex formation of rat liver lysyl-tRNA synthetase reduces enzyme lability to thermal inactivation. Biochemical and Biophysical Research Communications, 1982, 106, 44-47.	1.0	11
173	Protective effect of divalent cations in the plasmin degradation of fibrinogen. Archives of Biochemistry and Biophysics, 1985, 238, 452-457.	1.4	11
174	Stimulation of Myc transactivation by the TATA binding protein in promoter-reporter assays. BMC Biochemistry, 2005, 6, 7.	4.4	11
175	Turning publicly available gene expression data into discoveries using gene set context analysis. Nucleic Acids Research, 2016, 44, e8-e8.	6.5	11
176	c-myc Protooncogene., 2002,, 555-561.		10
177	Splicing and Dicing MYC-Mediated Synthetic Lethality. Cancer Cell, 2015, 28, 405-406.	7.7	10
178	Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation. Cancer Cell, 2010, 18, 397.	7.7	9
179	mTOR Senses Intracellular pH through Lysosome Dispersion from RHEB. BioEssays, 2019, 41, e1800265.	1.2	9
180	Glutamine Skipping the Q into Mitochondria. Trends in Molecular Medicine, 2020, 26, 6-7.	3.5	9

#	Article	IF	CITATIONS
181	Hydrodynamic properties and structure of the rat liver 12 S arginyl- and lysyl-tRNA synthetase complex. Biochemical and Biophysical Research Communications, 1983, 117, 464-469.	1.0	8
182	Feeding frenzy for cancer cells. Science, 2017, 358, 862-863.	6.0	8
183	A case of agnogenic myeloid metaplasia evolving into acute myelogenous leukemia associated with the development of trisomy 11 in bone marrow cells. American Journal of Hematology, 1985, 19, 285-288.	2.0	7
184	MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer. Cancer Cell, 2017, 32, 3-5.	7.7	7
185	Array-Based Nuclear Run-On Analysis. Methods in Molecular Biology, 2012, 809, 505-517.	0.4	7
186	Micro-managing and restraining pluripotent stem cells by MYC. EMBO Journal, 2009, 28, 3065-3066.	3.5	6
187	Bcl-xL Enforces a Slow-Cycling State Necessary for Survival in the Nutrient-Deprived Microenvironment of Pancreatic Cancer. Cancer Research, 2022, 82, 1890-1908.	0.4	6
188	Misregulation of Drosophila Myc Disrupts Circadian Behavior and Metabolism. Cell Reports, 2019, 29, 1778-1788.e4.	2.9	5
189	Measuring MYC-Mediated Metabolism in Tumorigenesis. Methods in Molecular Biology, 2021, 2318, 231-239.	0.4	5
190	Pancytopenia Secondary to Oxalosis in a 23-Year-Old Woman. Blood, 1998, 91, 4394-4394.	0.6	5
191	Detection and use of recombinant staphylococcal protein A fusion proteins to localize nucleic-acid-binding domains of proteins. Analytical Biochemistry, 1988, 174, 313-317.	1.1	4
192	c―MYC mRNA tail tale about glutamine control of transcription. EMBO Journal, 2017, 36, 1806-1808.	3.5	4
193	Autophagy: clocking in for the night shift. EMBO Journal, 2019, 38, .	3.5	4
194	Myoglobin tames tumor growth and spread. Journal of Clinical Investigation, 2009, 119, 766-768.	3.9	4
195	Q-ing tumor glutaminase therapy. Oncotarget, 2015, 6, 38440-38441.	0.8	3
196	Heparin requirement for the quantitation of fibrinogen production by primary hepatocyte cultures. Analytical Biochemistry, 1988, 170, 456-462.	1.1	2
197	Sex, life, and death in MYC-driven lymphomagenesis. Molecular Cell, 2021, 81, 3886-3887.	4.5	2
198	<i>Cancer Research</i> Celebrates the 50th Anniversary of the National Cancer Act and a Future of Hope. Cancer Research, 2021, 81, 5781-5782.	0.4	2

#	Article	IF	Citations
199	Celebrating the physician-scientist. Journal of Clinical Investigation, 2003, 112, S1-2.	3.9	2
200	Intranuclear location of the myositis-specific Jo-1 antigen: Hopping histidyl-tRNA synthetase?. Arthritis and Rheumatism, 1985, 28, 839-840.	6.7	1
201	Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. Journal of Biomedical Science, 1997, 4, 269-278.	2.6	1
202	Muscle Fatigue from Losing Your PHD. Cell Metabolism, 2008, 7, 191-192.	7.2	1
203	BETting on combination to overcome PARPi resistance. Oncotarget, 2017, 8, 84630-84631.	0.8	1
204	Essentiality of non-essential amino acids for tumour cells and tumorigenesis. Nature Metabolism, $2019, 1, 847-848$ .	5.1	1
205	MYC Regulation of Metabolism and Cancer. , 2015, , 101-122.		1
206	ORGANIZATION OF MAMMALIAN AMINOACYL-tRNA SYNTHETASES. , 1978, , 575-580.		1
207	Myc and Control of Tumor Neovascularization. , 2010, , 167-187.		1
208	Peer Review: Value Added and Civility. Cancer Research, 2022, 82, 1157-1158.	0.4	1
209	Edging toward New Therapeutics with Cyclin D1 Egl'ng on Cancer. Cancer Cell, 2009, 16, 361-362.	7.7	0
210	Old and fat, oncogenes make you. Cell Cycle, 2012, 11, 1272-1272.	1.3	0
211	Differential Regulation of MicroRNA Expression In Polycythemia Vera CD34+ Cells. Blood, 2010, 116, 4785-4785.	0.6	0
212	Warburg Effect. , 2011, , 3941-3945.		0
213	Myc Target Genes in Cell Proliferation and Programmed Cell Death. Medical Intelligence Unit, 1995, , 171-192.	0.2	0
214	Max Association with Myc. Medical Intelligence Unit, 1995, , 151-163.	0.2	0
215	Properties of the c-Myc Protein. Medical Intelligence Unit, 1995, , 109-118.	0.2	0
216	Warburg Effect. , 2017, , 4845-4849.		О